1. Home
  2. SLNH vs MGNX Comparison

SLNH vs MGNX Comparison

Compare SLNH & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Soluna Holdings Inc.

SLNH

Soluna Holdings Inc.

HOLD

Current Price

$1.69

Market Cap

263.4M

Sector

Technology

ML Signal

HOLD

Logo MacroGenics Inc.

MGNX

MacroGenics Inc.

HOLD

Current Price

$4.12

Market Cap

220.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLNH
MGNX
Founded
1961
2000
Country
United States
United States
Employees
52
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
263.4M
220.6M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
SLNH
MGNX
Price
$1.69
$4.12
Analyst Decision
Strong Buy
Buy
Analyst Count
1
5
Target Price
$5.00
$5.00
AVG Volume (30 Days)
19.3M
618.6K
Earning Date
05-15-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$149,500,000.00
Revenue This Year
$55.83
N/A
Revenue Next Year
N/A
$3.19
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.42
$1.19
52 Week High
$5.14
$4.64

Technical Indicators

Market Signals
Indicator
SLNH
MGNX
Relative Strength Index (RSI) 54.99 55.21
Support Level $1.50 $1.49
Resistance Level $1.74 $4.55
Average True Range (ATR) 0.20 0.25
MACD 0.01 -0.04
Stochastic Oscillator 70.31 47.29

Price Performance

Historical Comparison
SLNH
MGNX

About SLNH Soluna Holdings Inc.

Soluna Holdings Inc is a U.S.-based company engaged in the development and operation of data centers powered by renewable energy. The company utilizes excess or curtailed energy from renewable sources to support high-performance computing applications, including cryptocurrency mining, artificial intelligence, and machine learning. Its business model focuses on converting underutilized renewable energy into computing resources through co-located data center infrastructure.

About MGNX MacroGenics Inc.

Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.

Share on Social Networks: